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Abstract  
Objective  
Most investigations of pharmacotherapy for treating Alzheimer’s disease focus on 
patients with mild-to-moderate symptoms, with little evidence to guide clinical 
decisions when symptoms become severe. We examined whether continuing 
donepezil, or commencing memantine, is cost-effective for community-dwelling, 
moderate-to-severe Alzheimer’s disease patients.  
Methods  
Cost-effectiveness analysis was based on a 52-week, multicentre, double-
blind, placebo-controlled, factorial clinical trial. A total of 295 community-
dwelling patients with moderate/severe Alzheimer’s disease, already treated 
with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue 
donepezil; (iii) discontinue donepezil and start memantine; or (iv) continue 
donepezil and start memantine.  
Results  
Continuing donepezil for 52 weeks was more cost-effective than 
discontinuation, considering cognition, activities of daily living and health-
related quality of life. Starting memantine was more cost-effective than 
donepezil discontinuation. Donepezil-memantine combined is not more cost-
effective than donepezil alone. 
Conclusions   
Robust evidence is now available to inform clinical decisions and commissioning 
strategies so as to improve patients’ lives whilst making efficient use of available 
resources. Clinical guidelines for treating moderate/severe Alzheimer’s disease, 
such as those issued by NICE in England and Wales, should be revisited.  
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Introduction  
Understanding the resource consequences of dementia treatments is particularly 
pertinent given projected increases in prevalence (Prince et al, 2015) and 
associated expenditure (Comas-Herrera et al, 2007). Treatment decisions are 
increasingly informed by guidelines from bodies such as NICE, built on both clinical 
and cost-effectiveness evidence. In 2009, NICE revised its guidance on 
acetylcholinesterase (AChE) inhibitor treatment of patients with moderate 
dementia, recommending that treatment should stop at the severe stage. 
Following new economic modelling, NICE (2011) revised its guidance, allowing use 
of drugs within their licensed indications. A review of more recent evidence led to 
slightly updated guidance on medication treatment, with the three AChE inhibitors 
(donepezil, galantamine and rivastigmine) recommended as options for managing 
mild-to-moderate Alzheimer's disease (AD) and memantine recommended as an 
option for people with moderate AD who are intolerant of or have a 
contraindication to AChE inhibitors or with severe Alzheimer's disease (NICE 2016). 
There remains little evidence to guide clinical decision-making when patients reach 
moderate-to-severe AD. We therefore sought to examine the clinical and cost-
effectiveness consequences of continuing donepezil and commencing memantine 
(singly or in combination with donepezil). Clinical effectiveness findings have been 
published (Howard et al, 2012); here we examine the cost-effectiveness 
consequences. 
 
Method 
Participants  
Patients met standardised clinical criteria for probable/possible moderate or 
severe AD (McKhann et al, 1984), and had been continuously prescribed donepezil 
for >3 months. Their prescribing clinician was considering change of medication, 
based on discussions with patient and carer, NICE guidance and clinical judgement. 
Patients had sMMSE score of 5-13 (Molloy and Standish, 1997), were community-
living, and had a carer who was co-resident or visited at least daily. Patients were 
recruited from 15 NHS English and Scottish centres between February 2008 and 
March 2010. 
Design  
DOMINO-AD was a multicentre, double-blind, placebo-controlled, factorial (2x2) 
clinical trial, with assessment of outcomes and costs over 52 weeks. It compared 
four treatments: (i) continue donepezil 10mg per day with placebo memantine; (ii) 
discontinue donepezil (following 4 weeks donepezil 5 mg) with placebo memantine; 
(iii) discontinue donepezil and initiate memantine 20 mg per day; and (iv) continue 
donepezil 10 mg per day and initiate memantine 20 mg per day. Tablets were 
provided by the manufacturers. The study protocol was published before any data 
analysis (Jones et al, 2009). 
Ethics 
DOMINO-AD was registered with the ISRCTN Registry (ISRCTN49545035). Ethical 
approval was received from Scotland ‘A’ Multicentre Research Ethics Committee.  
An Independent Data Monitoring Committee reviewed efficacy and safety data 
every 6 months.  
Randomisation 
A prepared unrestricted randomised list of assignments was used for the first 80 
participants to ensure allocation concealment. Subsequent participants were 
randomly assigned to one of four treatment groups by the MRC CTU using 
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randomised minimisation. Groups were stratified by centre, duration of donepezil 
treatment before entry (3-6 months; >6 months), baseline sMMSE score (5-9; 10-13) 
and age (<60; 60-74; >74 years). Patients, caregivers, clinicians, outcome assessors 
and investigators were blinded to assignment. 
Outcomes  
Patients were assessed at baseline (pre-randomization), at week 6 post-
randomisation to assess short-term effects of donepezil withdrawal, and at weeks 
18, 30 and 52.  
Primary outcomes were: 
 cognition: sMMSE (range 0-30, higher scores indicate better cognitive function) 
rated by treating clinicians; 
 functioning in activities of daily living: Bristol Activities of Daily Living Scale 
(BADLS) Bucks et al, 1996) (range 0-60, higher scores indicate greater functional 
impairment) rated by carers. 
Secondary outcomes were: 
 behavioural and psychological symptoms: Neuropsychiatric Inventory (NPI) 
(Cummings et al, 1994) (range 0-144, higher scores indicate more symptoms) 
rated by treating clinicians; 
 dementia-specific health-related quality of life: DEMQOL-Proxy (Smith et al, 
2007) (range 31-134, higher scores indicate better quality of life) rated by 
carers; 
 generic health-related quality of life: EQ-5D-3L (EuroQol Group, 1990) rated by 
carers; 
 health status of family or other unpaid carers: General Health Questionnaire 
(GHQ-12) (Goldberg et al, 1997) (range 0-12, higher scores indicate increased 
psychological morbidity).  
The economic evaluation focused on three outcomes: sMMSE, BADLS, EQ-5D-3L. We 
applied societal weights to EQ-5D-3L (Dolan et al, 1995) to calculate utility values. 
Quality-adjusted life years (QALYs) were calculated by ‘area-under-the-curve’ 
analysis, with linear interpolation between assessment points.  
Before commencing data analysis, and based on the first 127 participants to 
complete DOMINO-AD, the research team published values for minimum clinically 
important differences on sMMSE (1.4 points), BADLS (3.5 points) and NPI (8 points), 
based upon 0.4 standard deviations of changes from baseline (Howard et al, 2011). 
Sample size 
Original planned sample size was 800, adjusted to 430 based on standard deviations 
of outcomes from a blinded analysis of accrued data. Allowing for expected 20% 
missing visits, at two-sided significance level of 5%, n=430 would give 95% power to 
detect a 1.0 point sMMSE difference and 90% power to detect a 2.0 point BADLS 
difference between donepezil and placebo, or between memantine and placebo, at 
52 weeks, and 96% power to detect a 1.5 point sMMSE difference, and 80% power to 
detect a 2.5 point BADLS difference between combination treatment and 
monotherapy at 52 weeks.  
Costs 
Data on services and unpaid support were collected for each patient at: 
 baseline (randomisation) for a retrospective period of 13 weeks; 
 6-week post-randomisation assessment retrospectively over 6 weeks; 
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 30-week assessment retrospectively over 24 weeks; 
 52-week assessment retrospectively over 22 weeks. 
Services and support data for patients were recorded on the Client Service Receipt 
Inventory (CSRI) (Beecham & Knapp, 2001) completed by family or professional 
carers, covering: inpatient stays, outpatient attendances, day hospital, social 
clubs, lunch clubs, day care, community-based professional contacts (e.g. 
psychologists, psychiatrists, GPs, nurses, social workers, occupational therapists, 
home care) and all other services. Costs were assumed to be incurred by health 
and social care agencies even though some individuals make co-payments. Data 
were also collected on volunteer support, befriending, telephone care-line support 
and unpaid support by family and friends.  
Unit costs reflecting long-run marginal opportunity costs were drawn from available 
public sources, set at 2013/14 prices. Costs per unit of measurement for each 
service type (e.g. per contact with health professional) were mainly taken from 
Curtis (2014); NHS Reference Costs (Department of Health, 2014) were used for 
inpatient and outpatient attendances. Costs of unpaid care were estimated from 
information on volume and type of support, the opportunity cost of lost work (wage 
rate) for carers in paid employment, and replacement cost for those not in paid 
employment based on cost of a home care worker (Curtis, 2014). 
Medication costs were applied over the treatment titration and maintenance 
schedules. Donepezil came off patent in 2012 and memantine in 2014; we attached 
prices obtained from pharmacies at study sites for the generic versions (4p per 5mg 
tablet and 6p per 10mg tablet of donepezil; 4p per 10mg tablet and 7p per 20mg 
tablet for memantine). (At the time of the trial, both donepezil and memantine 
were under patent; donepezil prices were £2.27 per 5mg tablet and £3.18 per 
10mg tablet, and memantine prices were £1.23 per 10mg tablet and £2.46 per 
20mg tablet. However, we use only generic prices in our analyses) 
Cost-effectiveness  
Research questions were: (a) is donepezil continuation more cost-effective than 
donepezil discontinuation over 52 weeks; (b) is memantine, singly or in 
combination with donepezil, more cost-effective than memantine placebo; and (c) 
is the combination of donepezil and memantine more cost-effective than donepezil 
alone. 
Primary cost-effectiveness analyses were conducted from a health and social care 
perspective. Cost subtotals were also calculated: trial medication costs; hospital 
costs (inpatient, outpatient, accident and emergency); and community-based 
health, social and primary care. In sensitivity analyses we adopted a societal 
perspective, adding unpaid care costs to health and social care service costs. 
BADLS, SMMSE and QALYs were used, in turn, as measures of effectiveness in the 
cost-effectiveness analyses.  
Statistical analysis  
Analyses were conducted on participants receiving at least one dose of trial 
medication (including placebo), applying intention-to-treat principles as far as 
practicably possible, given missing data. Participants were analysed in groups to 
which they were allocated irrespective of treatment discontinuation or open-label 
treatment. All non-missing scores at every visit (irrespective of whether patients 
were still on trial medication or switched to open-label treatment) were included; 
there was no imputation of missing scores. Full details of outcome analyses are 
given elsewhere (Howard et al, 2012).  
Cost data were analysed by regressing 52-week health and social care costs (or 
societal costs in secondary analyses) on treatment allocation, centre, age at 
 6 
baseline, duration of donepezil treatment pre-randomisation, baseline sMMSE and 
total health and social care costs (or societal costs) in the 13-week pre-
randomisation period. To mitigate effects of data skewness, non-parametric 
bootstrapping was used to estimate 95% confidence intervals (CIs) for mean costs. 
Where bias-corrected 95% CIs of between-group change scores excluded zero, they 
were judged significant at p=<0·05.  
The cost-effectiveness of one treatment over another was compared by calculating 
incremental cost-effectiveness ratios (ICERs), defined as difference in mean costs 
divided by difference in mean effects. If one treatment had lower costs and better 
outcome than its comparator it was considered dominant. Difficulties arise when 
one treatment is both more effective and more costly than its comparator, leaving 
the decision-maker to consider whether higher costs are justified by better 
outcomes. Cost-effectiveness acceptability curves (CEAC) (van Hout et al, 1994) 
were plotted for each cost-outcome combination to show the likelihood of one 
treatment being seen as cost-effective relative to another for a range of (implicit) 
values placed on incremental outcome improvements. Using the net benefit 
approach, monetary values of incremental effects and incremental costs were 
combined, and net benefit (NB) derived as: 
NB = λ x (effectb - effecta) – (costb – costa). 
λ is willingness-to-pay for a unit improvement in effectiveness (sMMSE, BADLS, 
QALYs), and a and b denote placebo and active treatment, respectively. A 
plausible range of λ values was explored for each outcome. This approach allows 
costs and outcomes to be considered on the same monetary scale, taking account 
of sampling uncertainty and adjusting for baseline covariates. 
Analyses were undertaken using STATA (version 11) and SPSS 17. 
Sensitivity analysis  
We explored consequences for cost-effectiveness of adopting a societal rather than 
health and social care perspective. 
 
Results 
Sample  
295 participants were recruited. Baseline characteristics were broadly comparable 
across treatments (Table 1). At baseline, full service use data and calculated costs 
were available for 291 (98.6%) participants (73 donepezil alone, 74 memantine 
alone, 72 donepezil-memantine combined, 72 placebo). By 52 weeks, health and 
social care cost data were available for 218 (73.9%) participants, and for all data 
collection points for 215 (72.9%). At 52 weeks, data on unpaid care were available 
for 186 (63.1%) participants and for all data collection points for 183 (62.0%). 
Thirty-nine patients died over the trial period, one lost to follow-up and 29 
withdrew. Unless noted otherwise, analyses from a health and social care 
perspective are based on 215 individuals, and analyses from a societal perspective 
on 183. 
Outcomes 
Effectiveness scores in Table 2 are not adjusted for baseline 
characteristics/centre; we do make adjustments for the cost-effectiveness 
analyses below. Howard et al (2012) detail the outcome analyses, where there was 
adjustment for the same variables except for pre-randomisation costs. Additionally 
adjusting for this cost covariate very slightly changes some numerical values for 
differences between treatments but does not change conclusions about relative 
effectiveness.  
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Compared to patients randomised to donepezil discontinuation, those continuing on 
donepezil had higher sMMSE scores (mean 1.7 points; 95% CI 0.5 to 2.8) and lower 
BADLS scores (-2.9 points; 95% CI -5.3 to 0.5). In other words, adjusted comparisons 
suggest that both cognitive and functional impairment deteriorated less for 
patients remaining on donepezil compared to those who stopped. There was a 
greater QALY gain for the donepezil group compared to placebo (mean 0.11; 95% CI 
0.02 to 0.20). 
Compared to patients randomised to memantine placebo, those given memantine 
had higher sMMSE scores (mean 1.0 points; 95% CI -0.1 to 2.0) and slightly lower 
BADLS scores (-1.7 points; 95% CI -3.9 to 0.6), after adjustment for baseline 
covariates. There was no difference in QALY gain between these two groups (0.07; 
95% CI -0.02 to 0.16). 
The differences between treatment with donepezil alone and treatment with 
donepezil and memantine combined were not statistically significant after 
adjustment for covariates, in terms of sMMSE (mean 0.3 points; 95% CI -1.4 to 2.0), 
BADLS (-1.1 points; 95% CI -7.2 to 5.1) or QALY gain (0.02; 95% CI -0.19 to 0.22). 
Costs 
Unadjusted health and social care costs were highest for people with placebo 
(£7,964) and lowest for those with memantine alone (£4,864); for people with 
donepezil-memantine combined, cost was £5,892, and for donepezil alone £5,418 
(Table 3). 
Unpaid care costs exceeded health and social care costs (Table 4). Societal costs 
were highest for people with memantine alone (£19,969), and lowest for those with 
donepezil-memantine combined (£16,058). Comparisons between these mean 
values should be tentative as they are not adjusted for baseline characteristics or 
centre. 
We compared costs for patients allocated to each treatment after adjusting for 
centre, age at baseline, duration on donepezil pre-randomisation, sMMSE at 
baseline and total costs prior to baseline (Table 5, top rows). There were no 
significant differences in health and social care costs or societal costs in any of the 
treatment comparisons.  
Cost-effectiveness analysis: health and social care perspective 
Incremental cost-effectiveness ratios (ICERs) for each outcome measure (BADLS, 
sMMSE, QALYs) were computed from a health and social care perspective (Table 5).  
Patients continuing on donepezil had slightly lower but not significantly different 
costs than patients who discontinued donepezil. Given that donepezil continuation 
was associated with better outcomes than discontinuation, donepezil thus 
dominates discontinuation. Cost-effectiveness acceptability curves (CEACs) allow 
us to summarise uncertainty in the estimates. The CEAC when outcome is measured 
by QALY gain (Figure 1) shows that the probability that donepezil continuation 
would be seen as more cost-effective than discontinuation is 93% at the £20,000 
threshold associated with NICE recommendations, and 96% at the £30,000 threshold 
(NICE, 2008). 
For the second treatment comparison, patients treated with memantine (with or 
without donepezil continuation) had slightly lower but not statistically significantly 
different costs than patients treated with memantine placebo (with or without 
donepezil continuation), while clinical outcomes were close to being statistically 
significantly better (Table 5). Memantine dominates memantine placebo from a 
health and social care perspective, and the CEAC when outcome is measured by 
QALY gain suggests that the probability of memantine being more cost-effective 
than memantine placebo is 92% at the £20,000 NICE threshold and 95% at the 
£30,000 threshold (Figure 2).  
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The cost-effectiveness analyses for the third comparison show that donepezil-
memantine combined had slightly higher adjusted health and social care costs 
compared to donepezil alone, although the difference was not statistically 
significant. Cost per QALY gained was £19,967 (Table 6). An alternative way to 
summarise results for the other two outcome measures is to calculate average cost 
of achieving a minimum clinically important difference; for BADLS the annual cost 
of achieving a 3.5-point difference is £2,622, and for sMMSE the annual cost of 
achieving a 1.4-point difference is £8,386. The CEAC with QALY as outcome shows 
that the probability that donepezil-memantine combined would be seen as more 
cost-effective than donepezil alone is only 50% at the £20,000 NICE threshold and 
55% at the £30,000 threshold (Figure 3). For BADLS and sMMSE, the CEACs again 
suggest low probabilities that donepezil-memantine combined would be seen as 
more cost-effective than donepezil alone, even at high willingness-to-pay values 
(Figure 3).  
Cost-effectiveness analysis: societal perspective 
We repeated the analyses from a societal perspective (Table 5). Outcome 
differences between treatments differ slightly between the rows in Table 5 
because of the smaller sample with a societal perspective.  
Donepezil continuation dominates donepezil discontinuation: better clinical 
outcomes and a reasonable, if not significant, societal cost advantage make 
donepezil continuation the more cost-effective option. 
Patients treated with memantine (with or without donepezil continuation) had 
slightly lower but not significantly different societal costs than patients treated 
with memantine placebo (with or without donepezil continuation), while clinical 
outcomes were not statistically significantly different. The CEACs (not shown) 
suggest reasonably high probabilities that memantine would be seen as more cost-
effective than memantine placebo when considering cognitive functioning (sMMSE, 
probabilities around 80%) or health-related quality of life (QALY, probabilities 
around 73%) but low probabilities (below 20%) when considering BADLS.  
In the third analysis, costs and outcomes were not observably different between 
donepezil alone and donepezil-memantine combined: cost and clinical outcome 
differences were tiny and not statistically significant. The probability that 
donepezil-memantine combined would be seen as more cost-effective than 
donepezil alone is modest (e.g. below 60% for all willingness-to-pay values for 
QALYs).  
 
Discussion  
Based on a double-blind, placebo-controlled trial of patients with moderate or 
severe Alzheimer’s disease already treated with donepezil, we found that 
continuation of donepezil treatment for a further 52 weeks was more cost-
effective than discontinuation. Donepezil’s cost-effectiveness was demonstrated 
regardless of whether outcomes were measured in terms of improvements in 
cognitive impairment, functional impairment or health-related quality of life, and 
whether costs were measured just for the health and social care system or for 
society as a whole.  
Starting memantine treatment was also more cost-effective than donepezil 
discontinuation from a health and social care perspectives by reference to all three 
outcome measures, and (though less strongly) was cost-effective from a societal 
perspective when considering cognition and health-related quality of life, but not 
when looking at functioning in activities of daily living. 
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In contrast, donepezil-memantine combined is not more cost-effective than 
donepezil alone by reference to NICE thresholds for QALY gains, and the economic 
case also looks weak when considering the other two outcomes that we analysed 
(BADLS and MMSE).  
Previous studies 
AChE inhibitors (such as donepezil) and memantine for the treatment of AD have 
been most frequently investigated for patients with mild-to-moderate symptoms. In 
moderate-to-severe AD (Feldman et al, 2001; Tariot et al, 2001) and severe AD 
(Fedldman et al, 2005; Winblad et al, 2006) AChE inhibitors are associated with 
modest improvements in cognition, function and clinical global impression. There is 
evidence that memantine is effective and cost-saving in moderate and severe AD 
(Areosa et al, 2005; Wimo et al, 2003) but it is not clear whether memantine in 
combination with an AChE inhibitor confers additional clinical benefits (Tariot et 
al, 2004; Porsteinsson et al, 2008). However, there is little evidence to guide 
decisions regarding treatment continuation when symptoms become severe and 
patients are still living at home.  
There is even less evidence on cost-effectiveness. Few economic evaluations of 
Alzheimer’s medications have been conducted within randomised controlled trials, 
although numerous studies have employed simulation models (Bond et al, 2012; 
Knapp et al, 2012). For donepezil, the only trial for patients with moderate-to-
severe AD with an economic evaluation found no cost difference compared to 
placebo over 24 weeks from a health system perspective and modest savings 
(CDN$332) from a societal perspective (Fedlman et al, 2001). For memantine, only 
modelling studies have been reported. For patients with mild-to-moderate 
dementia, AChE inhibitors enhance the effects of maintenance cognitive 
stimulation therapy and improve its cost-effectiveness (D’Amico et al, 2015). 
Post-hoc analyses of data from DOMINO-AD showed that discontinuation of 
donepezil increased the risk of nursing home placement during the 52-week trial 
period, although made no difference to this risk over the subsequent 4 years 
(Howard et al, 2015). Nursing home admissions account for a relatively small part 
of the overall cost of AD, but delaying admission can substantially reduce service-
related costs for people with more severe dementia (Knapp et al, 2016), even if it 
also risks increasing (prolonging) costs associated with unpaid care. We found that 
donepezil continuation was cost-effective even when unpaid care costs were 
included.  
The systematic review that informed the most recent NICE Guidance [UPDATE] on 
use of AD drugs identified very few trials with relevant data. The economic model 
found a probability of only 38% that memantine would be cost-effective at a 
willingness-to-pay of £30,000 per QALY (Bond et al, 2012), which is a lot lower than 
our finding here (94%). Our data therefore add to, and potentially change, the 
evidence base on the cost-effectiveness of pharmacotherapy for people with 
moderate/severe AD by suggesting that both donepezil and memantine are more 
cost-effective, when prescribed singly, than donepezil discontinuation. 
Limitations and strengths 
DOMINO-AD was unusual in evaluating medications for patients with more severe 
cognitive symptoms than has been common previously, specifically recruiting 
participants reaching the moderate-to-severe transition point. The study period of 
52 weeks was unusually lengthy. The trial was publicly funded (MRC, Alzheimer’s 
Society), and conducted independently. Both medications were covered by patent 
at the time of the trial, but are now both generic.  
The trial failed to recruit its target number of participants (410). This did not 
affect the power to detect significant differences on the co-primary outcomes 
(cognition and function) between donepezil and memantine and their respective 
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placebos, but may have contributed to failure to demonstrate significant cognitive 
or functional benefits of donepezil-memantine combined over donepezil alone. The 
factorial design of the trial, however, allowed us to demonstrate the individual 
benefits of donepezil and memantine regardless of whether medications were 
taken alone or combined. 
Estimating carer support costs is difficult: it is hard to measure time spent 
supporting someone with AD that is appropriately counted as ‘care’, and hard to 
attach an appropriate cost to that time. These common uncertainties in economic 
evaluation do not, of course, affect analyses from a health and social care 
perspective. We could not calculate carer costs for some patients, reducing sample 
size slightly for analyses from a societal perspective. 
Policy and practice implications 
The independently conducted DOMINO-AD trial offers new evidence on 
pharmacotherapy for Alzheimer’s disease patients who have progressed to the 
severe stage of their illness. The results have relevance for both clinical decision-
making (including decisions taken by health technology assessment bodies such as 
NICE) and for commissioning, given our findings on cost-effectiveness. For example, 
NICE guidelines can only recommend the use of a medication within its licensed 
indication. AChE inhibitors are not currently licensed in England and Wales for the 
treatment of severe AD, but only for mild-to-moderate AD. Memantine is 
recommended for treatment of moderate or severe AD (NICE 2016). 
The trial suggests a strong case – not only on clinical grounds but also on economic 
grounds – for patients who have been successfully treated with donepzil at the 
mild-to-moderate stages but who have now progressed to more severe disease 
either continuing with donepezil or switching to memantine.  
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Table 1. Baseline participant characteristics by treatment arm  
 
 
Donepezil 
alone 
Placebo  
Memantine 
alone 
Donepezil plus 
memantine 
Total entered in trial 73 73 76 73 
Age in years / Mean 77.2 77.7 76.2 77.5 
Gender; n (%) Male 22 (30%) 26 (36%) 30 (39%) 24 (33%) 
Previous duration of donepezil 
3-6 months 3 (4%) 3 (4%) 4 (5%) 4 (5%) 
>6 months 70 (96%) 70 (96%) 72 (95%) 69 (95%) 
Standardised Mini-Mental State 
Examination (sMMSE) 
Mean (sd) 9.0 (2.8) 9.1 (2.4) 9.2 (2.5) 9.1 (2.6) 
Bristol Activities of Daily Living 
Scale (BADLS) 
Mean (sd) 28.2 (9.0) 28.6 (8.9) 27.1 (9.0) 26.9 (9.8) 
Neuropsychiatric Inventory 
(NPI) 
Mean (sd) 22.3 (16.7) 22.9 (17.0) 23.1 (16.2) 20.3 (14.4) 
DEMQOL-Proxy Mean (sd) 98.3 (13.5) 101.4 (11.7) 96.5 (15.3) 98.3 (13.5) 
General Health Questionnaire 
(GHQ-12) 
Mean (sd) 2.3 (2.3) 2.8 (3.1) 3.1 (3.1) 1.8 (2.3) 
EQ-5D utility  Mean (sd) 0.57 (0.28) 0.55 (0.28) 0.59 (0.27) 0.55 (0.29) 
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Table 2. Clinical and quality of life measure scores (unadjusted for baseline 
characteristics) over time 
 
 Donepezil alone Placebo  Memantine alone 
Donepezil plus 
memantine 
 Mean (sd) Mean (sd) Mean (sd) Mean (sd) 
BADLS 
 Week 6 29 (9) 32 (9) 28 (9) 28 (10) 
 Week 18 31 (11) 37 (9) 33 (9) 30 (10) 
 Week 30 33 (11) 38 (9) 34 (11) 31 (10) 
 Week 52 37 (11) 41 (9) 37 (10) 35 (9) 
sMMSE 
 Week 6 9 (4) 8 (4) 9 (4) 10 (4) 
 Week 18 8 (4) 5 (4) 8 (4) 9 (5) 
 Week 30 6 (4) 5 (4) 6 (4) 8 (5) 
 Week 52 5 (5) 3 (3) 5 (5) 6 (4) 
Generic quality of life (EQ-5D utility) 
 Week 6 0.56 (0.28) 0.48 (0.28) 0.61 (0.26) 0.57 (0.28) 
 Week 18 0.52 (0.30) 0.40 (0.30) 0.52 (0.30) 0.56 (0.26) 
 Week 30 0.51 (0.32) 0.37 (0.29) 0.46 (0.29) 0.55 (0.26) 
 Week 52 0.48 (0.31) 0.26 (0.27) 0.42 (0.28) 0.49 (0.32) 
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Table 3. Mean unadjusted costs (£, 2013/14 prices) of trial medication, hospital care, 
community-based health and social care and primary care  
 
 Donepezil alone Placebo  Memantine alone 
Donepezil plus 
memantine 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Pre-baseline (13 weeks) - N 73 72 74 72 
Hospital care  1,516  (5,289) 489  (2,419) 327  (1,037) 398 (1,134) 
Community-based care 864 (2,205) 925 (2,852) 721 (2,019) 647 (1,932) 
Total cost 2,380 (5,977) 1,414 (3,972) 1,048 (2,322) 1,045 (2,187) 
Weeks 1-6 – N 72 71 73 68 
Trial medication 3  1  4  5  
Hospital care  149  (643) 246  (1,163) 254  (1,012) 93 (394) 
Community-based care 248 (687) 242 (667) 149 (265) 221 (451) 
Total cost 401 (939) 490 (1,445) 414 (1,122) 326 (695) 
Weeks 7-30 – N 63 60 60 63 
Trial medication 10  0  12  22  
Hospital care  1,178 (4,606) 1,747 (4,812) 764 (2,512) 792 (1,852) 
Community-based care 1,396 (2,607) 1,709 (5,877) 1,121 (2,525) 1,556 (4,222) 
Total cost 2,584 (5,086) 3,456 (7,919) 1,973 (3,397) 2,445 (4,570) 
Weeks 31-52 - N 54 55 51 58 
Trial medication 9  0  11  20  
Hospital care  940 (2,928) 597 (1,729) 829 (2,530) 758 (2,323) 
Community-based care 2,062 (3,713) 3,850 (17,929) 2,124 (3,854) 2,069 (3,547) 
Total cost  3,011 (4,493) 4,447 (17,944) 3,033 (4,580) 2,915 (4,365) 
Weeks 1-52 - N 53 55 51 56 
Total health & social care 
costs  
5,418 (7,464) 7,964 (23,707) 4,864 (7,416) 5,892 (8,607) 
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Table 4. Mean unadjusted costs (£, 2013/14 prices) of health and social care and unpaid 
carer support, and total societal costs 
 
 Donepezil alone Placebo  Memantine alone 
Donepezil plus 
memantine 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Pre-baseline (13 weeks) - N 73 72 74 72 
Health and social care 2,380 (5,977) 1,414 (3,972) 1,048 (2,322) 1,045 (2,187) 
Unpaid care 4,397 (7,844) 2,842 (5,725) 4,217 (6,470) 5,457 (7,802) 
Total societal cost 6,777 (10,351) 4,256 (6,737) 5,266 (6,734) 6,502 (7,959) 
Weeks 1-6 – N 72 71 73 68 
Health and social care 401 (939) 490 (1,445) 406 (1,122) 319 (695) 
Unpaid care 1,257 (2,144) 793 (1,425) 1,043 (1,616) 1,228 (2,533) 
Total societal cost 1,658 (2,319) 1,283 (1,888) 1,449 (1,846) 1,547 (2,613) 
Weeks 7-30 – N 62 58 60 62 
Health and social care 2,178 (3,967) 3,222 (7,733) 1,898 (3,397) 2,311 (4,583) 
Unpaid care 4,649 (8,366) 2,779 (5,586) 4,649 (6,618) 4,876 (5,808) 
Total societal cost 6,828 (9,254) 6,001 (9,167) 6,547 (7,634) 7,186 (7,922) 
Weeks 31-52 - N 47 41 43 52 
Health and social care 2,870 (4,202) 5,603 (20,703) 3,460 (4,832) 2,978 (4,508) 
Unpaid care 5,385 (7,341) 4,659 (7,312) 7,111 (11,641) 3,978 (5,905) 
Total societal cost 8,256 (7,725) 10,262 (22,558) 10,640 (12,556) 7,024 (7,844) 
Weeks 1-52 - N 46 41 43 50 
Health and social care 5,530 (7,592) 8,531 (27,015) 5,610 (7,855) 6,102 (8,943) 
Unpaid care 11,160 (15,035) 8,884 (13,182) 14,359 (17,968) 9,956 (11,815) 
Total societal cost 16,690 (15,846) 17,415 (29,871) 19969 (19,186) 16,058 (15,636) 
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Table 5. Mean adjusted cost differences, incremental costs and outcomes, and cost-
effectiveness ratios for each of the three treatment comparisons over weeks 1-52 
 
 Mean Difference* (95% CI) 
 Donepezil continuation vs 
donepezil discontinuation 
Memantine vs memantine 
placebo 
Donepezil and memantine 
combined vs donepezil 
alone 
Mean adjusted cost differences (component and total) (£, 2013/14 prices)  
Medication costs 20 26 46 
Hospital care 
costs  
-63 (-1,236 to 1,110) -594 (-1,768 to 580) -21 (-1,761 to 1,719) 
Community-based 
care costs 
-196 (-3,230 to 2,839) -1,288 (-4,465 to 1,889) 93 (-1,815 to 2,001) 
Unpaid care costs -2,037 (-4,385 to 311) -468 (-2,467 to 1,531) -1,875 (-4,309 to 559) 
Total health and 
social care costs 
-389 (-3,600 to 2,822) -1,409 (-4,912 to 2,094) 599 (-2,240 to 3,438) 
Total societal costs -2,669 (-7,262 to 1,923) -1,457 (-6,330 to 3,416) -331 (-4641 to 3,979) 
Health and social care perspective: incremental costs and effects*, mean (95% CI)  
Costs  -389 (-3,600 to 2,822) -1,409 (-4,912 to 2,094) 599 (-2,240 to 3,438) 
BADLS score  3.0 (0.7 to 5.2) 1.9 (-0.4 to 4.1) 0.8 (-3.5 to 5.2) 
sMMSE score  1.7 (0.6 to 2.7) 0.9 (-0.1 to 1.9) 0.1 (-1.5 to 1.6) 
QALY (EQ-5D)  0.11 (0.03 to 0.19) 0.07 (-0.01 to 0.16) 0.03 (-0.10 to 0.16) 
Health and social care perspective: incremental cost-effectiveness ratios* (£, 2013/2014 prices) 
… for BADLS Donepezil dominant Memantine dominant 749 
… for sMMSE Donepezil dominant Memantine dominant 5,990 
… for QALY Donepezil dominant Memantine dominant 19,967 
Societal perspective: incremental costs and effects*, mean (95% CI) 
Costs  -2,669 (-7,262 to 1,923) -1,457 (-6,330 to 3,416) -331 (-4,641 to 3,979) 
BADLS score  3.0 (0.7 to 5.3) 1.2 (-1.2 to 3.5) 1.1 (-2.5 to 4.7) 
sMMSE score  1.5 (0.4 to 2.7) 0.6 (-0.6 to 1.7) -0.3 (-1.8 to 1.1) 
QALY (EQ-5D)  0.09 (0.00 to 0.19) 0.02 (-0.08 to 0.12) 0.01 (-0.13 to 0.16) 
Societal perspective: incremental cost-effectiveness ratios* (£, 2013/2014 prices) 
… for BADLS Donepezil dominant Memantine dominant 301 
… for sMMSE Donepezil dominant Memantine dominant Donepezil dominant 
… for QALY Donepezil dominant Memantine dominant 33,100 
* Adjusted for centre, age, duration on donepezil, SMMSE score prior to randomisation and 
total costs at baseline. 
** Higher scores indicate better outcomes on all measures 
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Figure 1. Cost-effectiveness acceptability curve: donepezil continuation vs. 
discontinuation; health and social care perspective, with effectiveness measured in 
QALYs 
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Figure 2. Cost-effectiveness acceptability curve: memantine vs memantine placebo; 
health and social care perspective, with effectiveness measured in QALYs  
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Figure 3. Cost-effectiveness acceptability curves: donepezil and memantine vs. 
donepezil only; health and social care perspective, with effectiveness measured in 
QALYs, BADLS and MMSE 
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